Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS107 + toripalimab + chemotherapy versus sintilimab + chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20261753Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JS107 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started May 2026; status: active.
02
Drugs
JS107
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20261753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261753.